Zosano Pharma Corp (NASDAQ: ZSAN) is flying early on in the market this morning, and for good reason. The company announced the publication of clinical data that excited investors who are sending it screaming for the top. Today, we’ll talk about:
- The news;
- what we’re seeing from ZSAN stock as a result; and
- what we’ll be watching for ahead.
ZSAN Announces Clinical DAta
As mentioned above, Zosano Pharma is having an incredibly strong start to the trading session this morning after the company reported the publication of positive data from a clinical trial. In a press release issued early this morning, the company announced the recent publication of a peer-reviewed paper surrounding ADAM technology for the delivery of zolmitriptan. The paper was published in the Journal of Pharmaceutical Science. In a statement, Hayley Lewis, SVP of operations at ZSAN, had the following to offer:
This study enabled us to understand the delivery and tolerability of M207 in a nonclinical setting so as to aid us in setting reasonable expectations of our platform when studying in human subjects… The results from this animal study add to a growing body of evidence which indicate that absorption through the epidermis or dermis seems to be a suitable delivery platform for products that have limitations when delivered orally.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dabble in the market is that the news causes moves. In this particular case, the news proved to be overwhelmingly positive. The publication of the data in the Journal of Pharmaceutical Science further validates the company’s work. So, it’s no surprise to see that excited investors are sending the stock on a run for the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (11:10), ZSAN is trading at $4.74 per share after a gain of $0.60 per share or 14.49% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on ZSAN. In particular, we’re interested in following the story surrounding the company’s continued work regarding M207. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!